Pelvic sonography to help determine the appropriate therapy for luteal phase defects.
In some series the most appropriate therapy for luteal phase defects is supplemental progesterone in the luteal phase. Clomiphene's efficacy is more controversial since in one series only 8% achieved a successful pregnancy versus 45% in another study. Pelvic sonography was used to evaluate follicular development and release of the ovum in 50 infertile women with luteal phase defects. The results showed that only 40% had "pure" luteal phase defects whereas 52% had immature follicles and 8% had unruptured follicles. Sixty-two percent of the patients had previous therapy for a luteal phase defect and failed to conceive. Sixty-eight percent of this group did conceive when ultrasound was used to determine the appropriate therapy. Thus ultrasound can be employed to determine if the women with a luteal phase defect should be treated with a fertility drug, e.g., clomiphene or just with luteal phase progesterone support. Supplemental progesterone might still be needed with clomiphene based on repeat endometrial biopsy results.
D001971:Bromocriptine / Q000627:therapeutic use; D002996:Clomiphene / Q000627:therapeutic use; D005260:Female; D005498:Follicular Phase; D006801:Humans; D007247:Infertility, Female / Q000175:diagnosis* / Q000188:drug therapy; D008183:Luteal Phase; D010062:Ovulation Induction; D011374:Progesterone / Q000097:blood / Q000627:therapeutic use; D014463:Ultrasonography
D002996:Clomiphene; D001971:Bromocriptine; D011374:Progesterone